Autologous Basal Layer Stem Cells to Treat Bronchiectasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase interventional study will harvest a patient’s own bronchial basal layer stem cells, expand them outside the body, and reintroduce them via bronchoscopic infusion. The aim is to assess safety and preliminary effectiveness in adults with chronic structural lung disease due to bronchiectasis. Eligible participants are 25 to 80 years old with confirmed bronchiectasis and specific lung function thresholds. Exclusion criteria include pregnancy, active cancer, and certain infectious diseases. The trial is led by Ruijin Hospital with multiple collaborating sites in Shanghai and Hainan, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 25-80 years.
2. Confirmed diagnosis of bronchiectasis.
3. FEV1 ≥35% predicted; DLCO ≥30% and \<80% predicted.

Exclusion Criteria:

1. Pregnancy, lactation, or plans for pregnancy within 1 year.
2. Active malignancy or history of malignancy.
3. Positive serology for HIV, HBV, HCV, or syphilis.

Where it's running

• Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine
  Qionghai, Hainan, China Recruiting
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

• Tele-Pulmonary Rehabilitation for Chronic Lung Diseases

  This study tests whether a remote tele-rehabilitation program helps people with chronic lung diseases start and stick with pulmonary rehab better than usual center-based care.

  Recruiting at 2 sites Tel-Aviv Sourasky Medical Center · Ashkelon and 1 other locations · NCT07666841

• Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups

  This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 4 Assiut University · Asyut · NCT07608328

• Wearable sensors and AI to detect chest infection flare-ups in adults with cystic fibrosis or bronchiectasis

  This study will try wearable sensors and AI to see if changes in breathing or heart rate can spot chest infection flare-ups early in adults with cystic fibrosis or bronchiectasis who are starting IV antibiotics.

  Recruiting Papworth Hospital NHS Foundation Trust · Cambridge, Cambridgeshire · NCT07289100

• Home use of the LibAirty airway clearance system for adults with bronchiectasis

  This project will see if using the LibAirty airway clearance system at home reduces pulmonary exacerbations and improves symptoms for adults with bronchiectasis.

  Recruiting at 3 sites Synchrony-Medical, Ltd · Birmingham, Alabama and 2 other locations · NCT07135284

• Investigating how cold viruses affect bronchiectasis exacerbations

  This study is trying to see if cold viruses make symptoms worse for people with bronchiectasis compared to healthy individuals.

  Recruiting Imperial College London · London · NCT06931002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.